TY - JOUR
T1 - Immune correlates of protection for dengue
T2 - State of the art and research Agenda
AU - Participants in the Summit on Dengue Immune Correlates of Protection
AU - Katzelnick, Leah C.
AU - Harris, Eva
AU - Baric, Ralph
AU - Coller, Beth Ann
AU - Coloma, Josefina
AU - Crowe, James E.
AU - Cummings, Derek A.T.
AU - Dean, Hansi
AU - De Silva, Aravinda
AU - Diamond, Michael S.
AU - Durbin, Anna
AU - Ferguson, Neil
AU - Gilbert, Peter B.
AU - Gordon, Aubree
AU - Gubler, Duane J.
AU - Guy, Bruno
AU - Elizabeth Halloran, M.
AU - Halstead, Scott
AU - Jackson, Nicholas
AU - Jarman, Richard
AU - Lok, Shee Mei
AU - Michael, Nelson L.
AU - Ooi, Eng Eong
AU - Papadopoulos, Athanasios
AU - Plotkin, Stanley
AU - Precioso, Alexander R.
AU - Reiner, Robert
AU - Rey, Felix A.
AU - Rodríguez-Barraquer, Isabel
AU - Rothman, Alan
AU - Schmidt, Alexander C.
AU - Screaton, Gavin
AU - Sette, Alessandro
AU - Simmons, Cameron
AU - St John, Ashley L.
AU - Sun, Wellington
AU - Thomas, Stephen
AU - Torresi, Joseph
AU - Tsang, John S.
AU - Vannice, Kirsten
AU - Whitehead, Stephen
AU - Wilder-Smith, Annelies
AU - Yoon, Kyu
PY - 2017/8/24
Y1 - 2017/8/24
N2 - Dengue viruses (DENV1-4) are mosquito-borne flaviviruses estimated to cause up to 400 million infections and 100 million dengue cases each year. Factors that contribute to protection from and risk of dengue and severe dengue disease have been studied extensively but are still not fully understood. Results from Phase 3 vaccine efficacy trials have recently become available for one vaccine candidate, now licensed for use in several countries, and more Phase 2 and 3 studies of additional vaccine candidates are ongoing, making these issues all the more urgent and timely. At the "Summit on Dengue Immune Correlates of Protection", held in Annecy, France, on March 8-9, 2016, dengue experts from diverse fields came together to discuss the current understanding of the immune response to and protection from DENV infection and disease, identify key unanswered questions, discuss data on immune correlates and plans for comparison of results across assays/consortia, and propose a research agenda for investigation of dengue immune correlates, all in the context of both natural infection studies and vaccine trials.
AB - Dengue viruses (DENV1-4) are mosquito-borne flaviviruses estimated to cause up to 400 million infections and 100 million dengue cases each year. Factors that contribute to protection from and risk of dengue and severe dengue disease have been studied extensively but are still not fully understood. Results from Phase 3 vaccine efficacy trials have recently become available for one vaccine candidate, now licensed for use in several countries, and more Phase 2 and 3 studies of additional vaccine candidates are ongoing, making these issues all the more urgent and timely. At the "Summit on Dengue Immune Correlates of Protection", held in Annecy, France, on March 8-9, 2016, dengue experts from diverse fields came together to discuss the current understanding of the immune response to and protection from DENV infection and disease, identify key unanswered questions, discuss data on immune correlates and plans for comparison of results across assays/consortia, and propose a research agenda for investigation of dengue immune correlates, all in the context of both natural infection studies and vaccine trials.
KW - Dengue virus
KW - Immune correlates of protection
KW - Immune correlates of risk
KW - Natural infection
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=85026309271&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2017.07.045
DO - 10.1016/j.vaccine.2017.07.045
M3 - Article
C2 - 28757058
AN - SCOPUS:85026309271
SN - 0264-410X
VL - 35
SP - 4659
EP - 4669
JO - Vaccine
JF - Vaccine
IS - 36
ER -